Agree on this one. I would really like to see PR replaced as Chair of the Board, whilst I am very much a believer in the product, there is starting to be a mounting number of governance issues, e.g. missing timeframes, confusing comments regarding overall timelines (R&D Conference). I think he is a great CEO and often says the right things, but actions are not always following. An experienced bio-tech Chair would be very good for the company in the long run, IMO.
Ann: IND QUESTIONS RECEIVED FROM US FDA, page-323
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.015(6.67%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.0¢ | 22.5¢ | $173.6K | 743.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 99346 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 131244 | 5 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |